Loading
A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by University Hospital Tuebingen, now recruiting.
Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy is a phase 2 interventional study registered as NCT07337876 by University Hospital Tuebingen, with 100 participants planned, started 2026-01-07 and due to reach its primary completion in 2029-01. Interventions recorded: Dose escalated radiotherapy using a 1.5 T MR-Linac. Conditions recorded: Rectal Cancer.
Linked to the technology MR-guided adaptive radiotherapy because the registry's title names it ("mr guided adaptive radiotherapy") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MR-guided adaptive radiotherapy, Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/